MOUNT LAUREL, N.J., March 11 /PRNewswire-FirstCall/ -- MedQuist Inc., the largest Medical Transcription Service Organization (MTSO) in the world, today announced its financial results for its full year and fourth quarter ended December 31, 2008.
Full Year Results
Net revenues for the year ended December 31, 2008 were $326.9 million compared to $340.3 million for the year ended December 31, 2007. The decrease includes $10.2 million of lower medical transcription revenue resulting primarily from lower medical transcription volume and lower pricing and $3.3 million of lower technology products revenue due primarily to reduced maintenance contracts.
The Company had an operating loss of $88.4 million for 2008 compared to a loss of $21.9 million for 2007. The 2008 operating loss includes a non cash pre-tax charge of $82.2 million for impairment of goodwill. The charge was determined as a result of the Company's annual impairment test conducted pursuant to Statement of Financial Accounting Standard No. 142. The charge resulted from a decline in the Company's share price during the fourth quarter. The 2008 operating loss also includes a $5.9 million charge related to the settlement of the Department of Justice (DOJ) investigation of the Company. The Company and the DOJ settled the investigation for a payment of $6.8 million of which $.9 million was previously recorded.
Adjusted EBITDA (Operating Loss excluding Depreciation, Amortization of intangible assets, Cost of investigation and legal proceedings, net, and the Goodwill impairment charge) was $27.7 million for the year ended 2008 compared to $.7 million for 2007, a $27.0 million increase.
Cost of revenues for the year ended December 31, 2008 was $230.4 million compared to $260.9 million for the year ended December 31, 2007. The $30.5 million decrease was due primarily to headcount reductions and lower medical transcription payroll costs.
Selling, general and administrative expenses declined $11.4 million or 18.4% to $50.9 million compared to $62.3 million in 2007. The decrease was due primarily to lower audit costs and workforce reductions.
Research and development costs increased $2.2 million to $15.9 million for the year ended December 31, 2008. This was due to higher staffing costs associated with additional investment in our Document Enterprise Platform (DEP) technology.
Fourth Quarter Results
Net revenues were $79.4 million for the three months ended December 31, 2008 compared to $80.1 million for the same period in 2007.
The Company had an operating loss of $79.6 million in the quarter ended December 31, 2008 compared to a loss of $12.4 million in the same period of 2007. The 2008 period included the non cash pre-tax charge for goodwill impairment of $82.2 million noted above. In addition, the cost of investigation and legal proceedings, net for the three months ended December 31, 2008 was $1.1 million compared to $6.5 million for the quarter ended December 31, 2007.
Adjusted EBITDA (Operating Loss excluding Depreciation, Amortization of intangible assets, Cost of investigation and legal proceedings, net, and the Goodwill impairment charge) was $8.2 million for the three months ended December 31, 2008 compared to a loss of $1.5 million for the same period in 2007. This improvement reflects lower cost of revenues of $8.1 million due to headcount reductions and lower medical transcription payroll costs and lower selling, general and administrative costs of $2.3 million.
As of December 31, 2008, the Company had $39.9 million of cash and cash equivalents and no debt.
In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, MedQuist has provided non-GAAP financial measurements. Management believes that the non-GAAP financial measures used to manage the business may provide users additional useful information. The tables attached to this press release include a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures and a description of why the non-GAAP financial measures are useful to investors.
Forward-Looking Statements
This report contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, the industry in which we operate and other matters, as well as management's beliefs and assumptions and other statements regarding matters that are not historical facts. These statements include, in particular, statements about our plans, strategies and prospects. For example, when we use words such as "projects," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "should," "would," "could," "will," "opportunity," "potential" or "may," variations of such words or other words that convey uncertainty of future events or outcomes, we are making forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are only predictions and, as such, are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. For a discussion of these risks, uncertainties and assumptions, any of which could cause our actual results to differ from those contained in the forward-looking statement, see the section of MedQuist's Annual Report on Form 10-K for the year ended December 31, 2008, entitled "Risk Factors" and discussions of potential risks and uncertainties in MedQuist's subsequent filings with the Securities and Exchange Commission.
MedQuist Inc. and Subsidiaries Consolidated Statements of Operations (In thousands, except per share amounts) Unaudited Three months ended For the year ended December 31, December 31, ------------ ------------ 2008 2007 2008 2007 ---- ---- ---- ---- Net revenues $79,387 $80,066 $326,853 $340,342 ------- ------- -------- -------- Operating costs and expenses: Cost of revenues 53,867 61,961 230,375 260,879 Selling, general and administrative 11,808 14,130 50,855 62,288 Research and development 3,346 3,622 15,848 13,695 Depreciation 3,049 2,948 11,950 10,988 Amortization of intangible assets 1,409 1,446 5,554 5,511 Cost of investigation and legal proceedings, net 1,096 6,539 16,403 6,083 Goodwill impairment charge 82,233 - 82,233 - Restructuring charges 2,137 1,821 2,055 2,756 ------- ------ ------- ------- Total operating costs and expenses 158,945 92,467 415,273 362,200 ------- ------ ------- ------- Operating loss (79,558) (12,401) (88,420) (21,858) Equity in income of affiliated company 36 178 236 625 Other income - - 438 - Interest income, net (163) 1,889 2,438 8,366 ---- ----- ----- ----- Loss before income taxes (79,685) (10,334) (85,308) (12,867) Income tax provision (benefit) (19,234) (63) (16,513) 2,339 ------- --- ------- ----- Net loss $(60,451) $(10,271) $(68,795) $(15,206) ======== ======== ======== ======== Net loss per share: Basic $(1.61) $(0.27) $(1.83) $(0.41) ------ ------ ------ ------ Diluted $(1.61) $(0.27) $(1.83) $(0.41) ------ ------ ------ ------ Weighted average shares outstanding: Basic 37,556 37,500 37,549 37,488 ------ ------ ------ ------ Diluted 37,556 37,500 37,549 37,488 ------ ------ ------ ------ MedQuist Inc. and Subsidiaries Consolidated Balance Sheets (In thousands) Unaudited December 31, December 31, 2008 2007 ---- ---- Assets Current assets: Cash and cash equivalents $39,918 $161,582 Accounts receivable, net 50,374 48,725 Income tax receivable 154 815 Other current assets 8,053 7,920 ----- ----- Total current assets 98,499 219,042 Property and equipment, net 15,785 21,366 Goodwill 40,545 125,505 Other intangible assets, net 39,877 42,262 Deferred income taxes 1,204 2,712 Other assets 6,295 6,885 ----- ----- Total assets $202,205 $417,772 ======== ======== Liabilities and Shareholders' Equity Current liabilities: Accounts payable $7,487 $12,754 Accrued expenses 11,994 18,989 Accrued compensation 11,204 14,826 Customer accommodation 12,055 18,459 Deferred income taxes 651 4,783 Deferred revenue 15,630 16,023 ------ ------ Total current liabilities 59,021 85,834 Deferred income taxes 799 15,151 --- ------ Other non-current liabilities 2,033 2,143 ----- ----- Commitments and contingencies Shareholders' equity: Common stock - no par value; authorized 60,000 shares; 37556 and 37544 shares issued and outstanding, respectively 237,907 236,412 Retained earnings (deficit) (99,198) 72,876 Accumulated other comprehensive income 1,643 5,356 ----- ----- Total shareholders' equity 140,352 314,644 ------- ------- Total liabilities and shareholders' equity $202,205 $417,772 ======== ======== MedQuist Inc. and Subsidiaries Consolidated Statements of Cash Flows (In thousands) Unaudited For the year ended December 31, ------------ 2008 2007 ---- ---- Operating activities: Net loss $(68,795) $(15,206) Adjustments to reconcile net loss to cash (used in) provided by operating activities: Depreciation and amortization 17,504 16,499 Equity in income of affiliated company (236) (625) Goodwill impairment charge 82,233 - Deferred income tax (benefit) provision (17,091) 1,878 Stock option expense 1,427 565 Stock based compensation - Board Members - 150 Provision for doubtful accounts 3,073 4,967 Loss on disposal of property and equipment 571 168 Changes in operating assets and liabilities: Accounts receivable (5,781) (1,359) Income tax receivable 661 957 Insurance receivable - 707 Other current assets (154) (276) Other non-current assets 134 646 Accounts payable (5,557) 1,981 Accrued expenses (7,050) (9,378) Accrued compensation (3,559) (727) Customer accommodation and quantification (5,651) (3,723) Deferred revenue (272) 592 Other non-current liabilities (211) 1,910 ---- ----- Net cash used in operating activities $(8,754) $(274) ------- ----- Investing activities: Purchase of property and equipment (6,574) (11,639) Proceeds from sale of investments 692 - Capitalized software (3,411) (2,035) Net cash used in investing activities (9,293) (13,674) ------ ------- Financing activities: Dividend paid (103,279) - Proceeds from exercise of stock options 68 10 -- -- Net cash (used in) provided by financing activities (103,211) 10 -------- -- Effect of exchange rate changes (406) 108 ---- --- Net decrease in cash and cash equivalents (121,664) (13,830) -------- ------- Cash and cash equivalents - beginning of year 161,582 175,412 ------- ------- Cash and cash equivalents - end of year $39,918 $161,582 ======= ======== Supplemental cash flow information: Cash (recovered) paid for income taxes $210 $(451) ---- ----- Accommodation payments paid with credits $740 $2,595 ---- ------ MedQuist Inc. and Subsidiaries Reconciliation of GAAP financial measures to the non-GAAP measures Adjusted EBITDA (In thousands) Unaudited Three months ended For the year ended December 31, December 31, ------------ ------------ 2008 2007 2008 2007 ---- ---- ---- ---- GAAP operating (loss) $(79,558) $(12,401) $(88,420) $(21,858) Add: Depreciation 3,049 2,948 11,950 10,988 Add: Amortization of intangible assets 1,409 1,446 5,554 5,511 Add: Cost of investigation and legal proceedings, net 1,096 6,539 16,403 6,083 Add: Goodwill impairment charge 82,233 - 82,233 - ------ ------- ------- ---- Adjusted EBITDA $8,229 $(1,468) $27,720 $724 ====== ======= ======= ====
Adjusted EBITDA is a financial measure not computed in accordance with United States generally accepted accounting principles, or GAAP. The Company believes that this non-GAAP measure, when presented in conjunction with comparable GAAP measures, is useful to both management and investors in analyzing the Company's ongoing business and operating performance. The Company believes that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view the Company's financial results in the way that management views financial results. Management believes Adjusted EBITDA is useful as supplemental measures of the Company's financial results because it removes costs not related to the Company's operating performance. Management believes that Adjusted EBITDA should be considered in addition to, but not as a substitute for items presented in accordance with GAAP that are presented in this press release. A reconciliation of Adjusted EBITDA to Operating income (loss) is provided above.
